Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Rosiglitazone142 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00656 | 35013417 | Sci Rep | Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver. | 2022 | Details |
| A02326 | 34417811 | Endocrinology | Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity. | 2021 | Details |
| A02440 | 34371198 | Prostaglandins Other Lipid Mediat | Lipocalin-type Prostaglandin D2 Synthase appears to function as a Novel Adipokine Preventing Adipose Dysfunction in response to a High Fat Diet. | 2021 | Details |
| A04933 | 33444819 | Cell Mol Gastroenterol Hepatol | Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver. | 2021 | Details |
| A05528 | 33218077 | Int J Mol Sci | PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. | 2020 | Details |
| A05612 | 33188625 | J Physiol Biochem | Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway. | 2020 | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | 2020 | Details |
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | 2020 | Details |
| A07170 | 32593899 | Environ Res | Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis. | 2020 | Details |
| A07793 | 32353385 | Toxicol Appl Pharmacol | Metabolomic-based assessment reveals dysregulation of lipid profiles in human liver cells exposed to environmental obesogens. | 2020 | Details |
| A08393 | 32128893 | J Gastroenterol Hepatol | Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway. | 2020 | Details |
| A08883 | 31953228 | Biochim Biophys Acta Mol Cell Biol Lipids | Effects of peptidoglycan on the development of steatohepatitis. | 2020 | Details |
| A09343 | 31783920 | Syst Rev | Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. | 2019 | Details |
| A09662 | 31654717 | Cell Signal | Identification of Nogo-B as a new molecular target of peroxisome proliferator-activated receptor gamma. | 2019 | Details |
| A10514 | 31307592 | Adv Pharmacol | Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. | 2019 | Details |
| A11743 | 30769284 | Redox Biol | Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. | 2019 | Details |
| A12923 | 30225267 | J Diabetes Res | Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats. | 2018 | Details |
| A13037 | 30171034 | Dis Model Mech | Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases. | 2018 | Details |
| A13079 | 30145577 | Ann Hepatol | Salidroside and Curcumin Formula Prevents Liver Injury in Nonalcoholic Fatty Liver Disease in Rats. | 2018 | Details |
| A13453 | 29964161 | Pharmacol Res | Human-based systems: Mechanistic NASH modelling just around the corner? | 2018 | Details |
| A14097 | 29589386 | Endocrinol Metab (Seoul) | Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14177 | 29550470 | Biochem Biophys Res Commun | PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway. | 2018 | Details |
| A15830 | 28691103 | J Clin Transl Res | Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. | 2017 | Details |
| A15912 | 28655690 | Pak J Pharm Sci | Metformin HCl has curative effect on rebuilding of ventricular diastolic functions in high-fat-diet fed rats. | 2017 | Details |
| A16016 | 28611274 | Ann Hepatol | Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. | 2018 | Details |
| A16076 | 28581362 | Future Cardiol | PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. | 2017 | Details |
| A16325 | 28458350 | Biol Pharm Bull | Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation. | 2017 | Details |
| A16569 | 28300213 | Sci Rep | Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. | 2017 | Details |
| A16692 | 28241279 | JAMA Intern Med | Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. | 2017 | Details |
| A17409 | 27797398 | Eur J Clin Invest | Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. | 2016 | Details |
| A17519 | 27759627 | Medicine (Baltimore) | Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. | 2016 | Details |
| A17839 | 27545964 | Sci Rep | Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice. | 2016 | Details |
| A17856 | 27522101 | Drug Metab Pers Ther | Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. | 2016 | Details |
| A17878 | 27506737 | Metabolism | Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. | 2016 | Details |
| A18317 | 27216550 | J Cell Physiol | Association Between Aerobic Exercise and Rosiglitazone Avoided the NAFLD and Liver Inflammation Exacerbated in PPAR-α Knockout Mice. | 2016 | Details |
| A18452 | 27125895 | AAPS J | Dual Outcomes of Rosiglitazone Treatment on Fatty Liver. | 2016 | Details |
| A18880 | 26889237 | Exp Ther Med | Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. | 2015 | Details |
| A19078 | 26775807 | Sci Rep | Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. | 2016 | Details |
| A20041 | 26194065 | Cytokine | PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. | 2015 | Details |
| A20055 | 26189925 | Hepatology | Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. | 2015 | Details |
| A21310 | 25414939 | Postgrad Med | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. | 2014 | Details |
| A21705 | 25105443 | Ann Transplant | Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis. | 2014 | Details |
| A22333 | 24653581 | Afr J Tradit Complement Altern Med | Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats. | 2013 | Details |
| A22461 | 24550584 | Indian J Pharmacol | Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice. | 2014 | Details |
| A22471 | 24534255 | Toxicol Appl Pharmacol | PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. | 2014 | Details |
| A22672 | 24373179 | Diabetes Obes Metab | APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. | 2014 | Details |
| A22799 | 24295779 | Biochim Biophys Acta | Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice. | 2014 | Details |
| A23009 | 24118921 | Hepatol Res | Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage. | 2013 | Details |
| A23200 | 23965360 | Endocr J | Rosiglitazone attenuates casein-induced hepatic endoplasmic reticulum stress in Sprague-Dawley rats: a novel model of endoplasmic reticulum stress. | 2013 | Details |
| A23726 | 23531105 | Lipids Health Dis | Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective. | 2013 | Details |
| A23796 | 23476686 | Evid Based Complement Alternat Med | Managing the combination of nonalcoholic Fatty liver disease and metabolic syndrome with chinese herbal extracts in high-fat-diet fed rats. | 2013 | Details |
| A23950 | 23356584 | Liver Int | Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. | 2013 | Details |
| A24655 | 25755424 | J Clin Exp Hepatol | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. | 2012 | Details |
| A24752 | 22536512 | Int J Hepatol | Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease. | 2012 | Details |
| A24756 | 22532295 | Arch Pharm (Weinheim) | Synthesis and evaluation of 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of non-alcoholic fatty liver disease. | 2012 | Details |
| A24864 | 22420611 | Clin Sci (Lond) | Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. | 2012 | Details |
| A25238 | 22059955 | Health Technol Assess | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. | 2011 | Details |
| A25246 | 22050199 | Aliment Pharmacol Ther | Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. | 2011 | Details |
| A25305 | 21983273 | Biochim Biophys Acta | Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. | 2011 | Details |
| A25342 | 21946918 | Mol Med Rep | Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet. | 2011 | Details |
| A25499 | 21765869 | Therap Adv Gastroenterol | The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. | 2011 | Details |
| A25510 | 21755261 | Braz J Med Biol Res | Effect of silybin on high-fat-induced fatty liver in rats. | 2011 | Details |
| A25518 | 21748770 | Hepatology | Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. | 2011 | Details |
| A25641 | 21612059 | Vnitr Lek | [Steatosis and steatohepatitis in diabetic patient]. | 2011 | Details |
| A25721 | 21507897 | FASEB J | Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. | 2011 | Details |
| A25815 | 21430606 | Pol Arch Med Wewn | Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. | 2011 | Details |
| A26169 | 20965162 | Eur J Pharmacol | The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. | 2010 | Details |
| A26190 | 20938947 | Hepatology | Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. | 2010 | Details |
| A26254 | 20828853 | J Hepatol | Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. | 2010 | Details |
| A26478 | 20415685 | Diabetes Obes Metab | The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26556 | 20210788 | Basic Clin Pharmacol Toxicol | Hepatic effects of rosiglitazone in rats with the metabolic syndrome. | 2010 | Details |
| A26709 | 19921118 | Adv Ther | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. | 2009 | Details |
| A26791 | 19779336 | Curr Opin Lipidol | Thiazolidinediones and the liver in humans. | 2009 | Details |
| A26844 | 19667999 | Eur J Gastroenterol Hepatol | Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. | 2010 | Details |
| A27148 | 19084941 | World J Gastroenterol | Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. | 2008 | Details |
| A27163 | 19065650 | Hepatology | Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. | 2009 | Details |
| A27411 | 18445142 | Aliment Pharmacol Ther | Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. | 2008 | Details |
| A27417 | 18422468 | Expert Opin Pharmacother | Pleiotropic effects of thiazolidinediones. | 2008 | Details |
| A27421 | 18417155 | Life Sci | The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. | 2008 | Details |
| A27537 | 18171348 | J Gastroenterol Hepatol | PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. | 2008 | Details |
| A27587 | 17983937 | Endocrinol Metab Clin North Am | Use of insulin sensitizers in NASH. | 2007 | Details |
| A27695 | 17654601 | Hepatology | Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. | 2007 | Details |
| A27932 | 16959622 | J Formos Med Assoc | Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. | 2006 | Details |
| A27964 | 16865780 | World J Gastroenterol | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. | 2006 | Details |
| A27984 | 16796890 | Zhonghua Yi Xue Za Zhi | [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. | 2006 | Details |
| A28044 | 16610015 | World J Gastroenterol | Treatment of nonalcoholic fatty liver disease. | 2006 | Details |
| A28165 | 16231594 | Eur Rev Med Pharmacol Sci | The treatment of NAFLD. | 2006 | Details |
| A28339 | 15598336 | Pediatr Transplant | Non-alcoholic steatohepatitis in children. | 2004 | Details |
| A28350 | 15542525 | Gut | Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. | 2004 | Details |
| A28459 | 14585234 | Curr Treat Options Gastroenterol | Treatment of Nonalcoholic Fatty Liver Disease. | 2003 | Details |
| A28672 | 35162986 | Int J Mol Sci | Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease. | 2022 | Details |
| A30665 | 32025605 | Hepatol Commun | Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. | 2019 | Details |
| A31405 | 30633968 | Eur J Pharm Sci | Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. | 2019 | Details |
| A32145 | 29116096 | Sci Rep | AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M. | 2017 | Details |
| A35552 | 20376096 | Gene Ther | PPARgamma is essential for protection against nonalcoholic steatohepatitis. | 2010 | Details |
| A35700 | 19877169 | Hepatology | Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. | 2010 | Details |
| A36112 | 18991162 | Scand J Gastroenterol | Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. | 2009 | Details |
| A36297 | 18503774 | Gastroenterology | Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. | 2008 | Details |
| A36597 | 17661371 | Hepatology | The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. | 2007 | Details |
| A36622 | 17594812 | Zhonghua Gan Zang Bing Za Zhi | [An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis]. | 2007 | Details |